Skip to main content
. 2022 Sep 27;13:989275. doi: 10.3389/fimmu.2022.989275

Figure 3.

Figure 3

Comparison of survival in immunotherapy or chemotherapy arms using ML-signature (ICI-benefit vs. ICI-non-benefit) and TMB (high vs. low). (A, B) immunotherapy cohort, (C, D) chemotherapy cohort.